Opthea Total Liabilities 2021-2024 | OPT

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Opthea total liabilities from 2021 to 2024. Total liabilities can be defined as the total value of all possible claims against the corporation.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Opthea total liabilities from 2021 to 2024. Total liabilities can be defined as the total value of all possible claims against the corporation.

Related Stocks
Company Name	Market Cap
Amgen (AMGN)	$160.1B
Vertex Pharmaceuticals (VRTX)	$123.9B
Gilead Sciences (GILD)	$122.2B
Bristol Myers Squibb (BMY)	$116.5B
CSL (CSLLY)	$82.8B
Regeneron Pharmaceuticals (REGN)	$79.3B
GSK (GSK)	$75.4B
Argenex SE (ARGX)	$40B
Alnylam Pharmaceuticals (ALNY)	$35.9B
BioNTech SE (BNTX)	$28.8B
BeiGene (ONC)	$22.4B
Biogen (BIIB)	$20.7B
Illumina (ILMN)	$19.5B
Insmed (INSM)	$14.5B
Incyte (INCY)	$14.4B
Intra-Cellular Therapies (ITCI)	$13.5B
Moderna (MRNA)	$12.9B
Genmab (GMAB)	$12.8B
Genmab (GNMSF)	$12.7B
BioMarin Pharmaceutical (BMRN)	$12.3B
Bio-Techne Corp (TECH)	$11.9B
Vaxcyte (PCVX)	$11.1B
Swedish Orphan Biovitrum (BIOVF)	$10.9B
Sarepta Therapeutics (SRPT)	$10.7B
Exact Sciences (EXAS)	$10B
Bio-Rad Laboratories (BIO.B)	$9.6B
Exelixis (EXEL)	$9.6B
QIAGEN (QGEN)	$9.4B
Repligen (RGEN)	$9.1B
Roivant Sciences (ROIV)	$7.9B